Insufficient Radiofrequency Ablation Promotes Epithelial-mesenchymal Transition Mediated by Interleukin-6/signal Transducer and Activator of Transcription 3/Snail Pathway in the H22 Cells
Overview
Affiliations
Context: Radiofrequency ablation (RFA), an established and minimally invasive therapy for hepatocellular carcinoma, has become an important treatment strategy. However, tumor aggressiveness remains a common problem. The epithelial-mesenchymal transition (EMT) is thought to play an important role in this process.
Design And Aims: Due to limited sample volumes harvested from patients, we established a heat-treated cell line and a mouse model to investigate the mechanisms of incomplete ablation in EMT.
Materials And Methods: We heat-treated H22 and HepG2 cells using a water bath to determine a suitable temperature for incomplete RFA. Male BALB/c mice were orthotopically transplanted with H22 cells and then subjected to incomplete ablation. Changes in the EMT biomarkers were detected by real-time polymerase chain reaction, western blotting, and immunofluorescence.
Statistical Analysis: The experimental results are expressed as means ± standard deviations.
Results: Incomplete RFA promoted EMT, downregulated E-cadherin, upregulated vimentin and Snail, and enhanced the phosphorylation of signal transducer and activator of transcription 3 (STAT3) both in vivo and in vitro. Moreover, interleukin (IL)-6 secretion increased after heat treatment in the H22 cells. AG490, an IL-6 inhibitor, inhibited the occurrence of EMT.
Conclusions: Insufficient ablation performed at low temperature successfully induces EMT and promotes tumor aggressiveness, which is mediated by the IL-6/STAT3/Snail pathway in both cell and mouse models.
Frenkel N, Poghosyan S, van Wijnbergen J, Borel Rinkes I, Kranenburg O, Hagendoorn J Surg Open Sci. 2024; 18:29-34.
PMID: 38318321 PMC: 10838949. DOI: 10.1016/j.sopen.2024.01.005.
Fu Y, Zeng C, An C, Liu Y, Shin J, Li X Cancers (Basel). 2023; 15(4).
PMID: 36831664 PMC: 9954096. DOI: 10.3390/cancers15041324.
Chen S, Zeng X, Su T, Xiao H, Lin M, Peng Z Front Immunol. 2022; 13:1033000.
PMID: 36505437 PMC: 9726793. DOI: 10.3389/fimmu.2022.1033000.
Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research.
Wu S, Li Z, Yao C, Dong S, Gao J, Ke S Front Oncol. 2022; 12:1032746.
PMID: 36483051 PMC: 9723167. DOI: 10.3389/fonc.2022.1032746.
An Overview of Hepatocellular Carcinoma After Insufficient Radiofrequency Ablation.
Guo Y, Ren Y, Dong X, Kan X, Zheng C J Hepatocell Carcinoma. 2022; 9:343-355.
PMID: 35502292 PMC: 9056053. DOI: 10.2147/JHC.S358539.